NEW YORK, April 13, 2018 /PRNewswire/ --WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on MYL, MNTA, RIGL, and SCYX which can be accessed for free by signing up to www.wallstequities.com/registration. On Thursday, the NASDAQ Composite ended the day at 7,140.25, up 1.01%; the Dow Jones Industrial Average
Canonsburg, Pennsylvania headquartered Mylan N.V.'s stock finished Thursday's session 2.15% higher at $41.26 with a total trading volume of 4.44 million shares. The stock has gained 7.31% in the previous twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 0.36% and 7.67%, respectively. Moreover, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have a Relative Strength Index (RSI) of 52.96.
On April 12th, 2018, research firm Leerink Partners upgraded the Company's stock rating from 'Market Perform' to 'Outperform'. Get the full research report on MYL for free by clicking below at:
Shares in Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc. rose 1.03%, ending yesterday's session at $19.70 with a total trading volume of 934,798 shares, which was higher than their three months average volume of 871.39 thousand shares. The stock has gained 41.73% in the previous three months and 48.12% over the past twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 13.29% and 24.82%, respectively. Moreover, shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 64.63. Gain free access to the research report on MNTA at:
On Thursday, South San Francisco, California-based Rigel Pharmaceuticals Inc.'s stock saw a rise of 16.72%, to close the day at $3.91. A total volume of 19.70 million shares was traded, which was higher than their three months average volume of 1.65 million shares. The Company's shares have advanced 24.13% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 2.08% and 15.44%, respectively. Additionally, shares of Rigel Pharma, which engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases, have an RSI of 56.02. Register for your free report coverage on RIGL at:
Shares in Jersey City, New Jersey headquartered SCYNEXIS Inc. ended the day 1.56% higher at $1.30. A total volume of 151,943 shares was traded. The Company's shares are trading below their 50-day moving average by 16.50%. Furthermore, shares of SCYNEXIS, which develops and commercializes anti-infectives to address unmet therapeutic needs, have an RSI of 35.75. Get the free research report on SCYX at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/generic-drugs-stocks-research-reports-released-on-mylan-momenta-pharma-rigel-pharma-and-scynexis-300629467.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...
Acanthosis nigricans is a skin condition in which discoloration and hyperpigmentation of the skin ...
Gastrointestinal Bleeding refers to hemorrhage that occurs from one or more portions of the ...View All